Communication process involves the two parties participating regardless of the means of communication. If I call your name, you ought to hear it’s your name called; then you respond. The same applies to telecommunications. The use of emails is effective, fast and cheap but it has one major drawback, – it may go unanswered. You may ask yourself why? Well, your recipient could be receiving tens of emails a day, or even hundreds! Many of those emails are junk, not necessary, spam or promotional emails and they hinder effective communication by burying important emails amidst them.
Lucky enough, you have got Jojo Hedaya with his innovative tool called “Unroll me” to sort you out of the mess of receiving a whole lot of emails. “Unroll me” is an emails-organizing tool that scans all the emails in your inbox and within a few seconds and it categorizes them based on their nature or subject. The 30-year old Jojo Hedaya together with his counterpart Josh created this tool out of the frustration they were facing of ineffective mail communication from lack of replies secondary to too many promotional emails inbox.
The young entrepreneurs were brought up in New York, but they first met in Israel where they had traveled to further their studies. Since Jojo Hedaya and Josh’s discovered the coincidence that they shared birthdays, they almost perceived that their friendship was extraordinary. Their birthday was on December 30, 1989.
Despite not meeting the requirement to graduate, Jojo doesn’t regret. He would agree with anyone who would prefer quitting school to start up a company. Jojo Hedaya perceives that experience is better than a degree. He believes that one only needs education if they do not have the skills then it is justifiable that you pursue your degree first rather than thinking of starting a company.
Renovia is a biotech startup that Marc Beer initiated in Boston back in 2016 with the goal of developing treatments for various disorders, particular pelvic floor disorder. The series of funding performed by Marc in 2018 was able to generate more than 40 million dollars in funds to go towards new research and product development, making the road forward a little brighter in the healthcare community throughout Boston.
Pelvic floor disorder is not necessarily a life-threatening disease, but it does affect hundreds of millions of women all around the world today. This disorder is uncomfortable and even painful to live with, in most cases, which is why Marc Beer has made Renovia one of the first medical companies to focus on it.
The community has a positive outlook on Renovia as well, with many generous supporters throughout the healthcare community. Various investors have been Renovia, including Ascension Ventures, The Longwood Fund, and Perceptive Advisors. Learn more: https://www.bizjournals.com/boston/potmsearch/detail/submission/6457372/Marc_Beer
In April of last year, Renovia was able to get the approval of the FDA for its first product to treat pelvic floor disorder patients known as Leva. Leva acts as a digital health system and they still have a lot of work to do in order to make it optimal for the millions of women out there dealing with pelvic floor disorder.
Marc Beer has more than two decades of experience working in the pharmaceutical and biotech industries and he is experienced in the commercialization and development of products to treat disorders. Marc has personally developed other drugs in the past to treat various conditions, such as high cholesterol. Renovia is the first attempt by Marc Beer to develop products under the backing of a company, which was the basis on which the FDA didn’t approve his former products.
Currently, Renovia ahs Leva on the market and it is still being tested and developed. At the same time, Renovia also has several other products in the works, though they are not yet ready to be approved by the FDA. With more than 200 million women around the world facing pelvic floor disorder, based on scientist estimates, Renovia could prove one of the most beneficial biotech companies on the market for women’s health in the near future.